CAMP Camp4 Therapeutics Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1736730 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY39.9%
TTM net income YoY-126.8%
TTM EPS YoY-103.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,001.1%
Net margin-2,276.3%
FCF margin-496.4%
EBITDA margin-965.5%
Returns
ROE-146.1%
ROA-109.9%
ROIC (approx.)—
Asset turnover0.05x
Leverage & solvency
Liabilities / assets20.1%
Debt / equity0.00x
Current ratio6.42x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.21x
Accruals ratio-86.7%
Payout ratio—
Capex / revenue16.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.90M | $1.78M | $1.29M | $348,000 | $795,000 | $1.50M | $858,000 | $652,000 |
| R&D expense | $11.43M | $10.82M | $10.16M | $8.36M | $9.85M | $10.34M | $10.15M | $10.00M |
| SG&A expense | $4.49M | $4.34M | $4.21M | $4.77M | $4.60M | $4.18M | $3.81M | $4.69M |
| Operating income | -$14.03M | -$13.38M | -$13.07M | -$12.78M | -$13.65M | -$13.03M | -$13.10M | -$14.03M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$28.96M | -$33.53M | -$18.33M | -$40.28M | -$15.10M | -$12.59M | -$12.43M | -$13.28M |
| EBITDA | -$13.53M | -$12.88M | -$12.55M | -$12.40M | -$13.25M | -$12.63M | -$12.68M | -$13.62M |
| EPS (basic) | -0.37 | -0.58 | -0.32 | — | -0.55 | -0.62 | -0.62 | — |
| EPS (diluted) | -0.37 | -0.58 | -0.32 | — | -0.55 | -0.62 | -0.62 | — |
| Dividends declared per share | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 78.95M | 57.93M | 57.92M | — | 27.27M | 20.16M | 20.15M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $124.52M | $86.40M | $99.21M | $109.52M | $76.88M | $40.68M | $50.95M | $65.66M |
| Current assets | $127.54M | $90.03M | $102.20M | $114.09M | $77.71M | $41.09M | $51.67M | $66.38M |
| PP&E, net | $1.68M | $1.85M | $1.93M | $2.34M | $2.90M | $3.41M | $3.60M | $3.86M |
| Total assets | $134.01M | $93.43M | $105.46M | $117.81M | $86.39M | $51.27M | $62.77M | $78.31M |
| Current liabilities | $19.86M | $19.14M | $16.62M | $15.51M | $7.90M | $7.33M | $6.44M | $9.60M |
| Total liabilities | $26.92M | $94.12M | $74.56M | $70.10M | $27.73M | $11.29M | $11.20M | $15.16M |
| Shareholders' equity | $107.09M | -$693,000 | $30.90M | $47.70M | $58.67M | $39.99M | $51.57M | $63.14M |
| Shares outstanding | 62.75M | 51.93M | 51.93M | 51.90M | 46.88M | 20.16M | 20.16M | 20.15M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.16M | -$12.69M | -$10.98M | $6.29M | -$11.22M | -$10.34M | -$14.29M | -$11.29M |
| Capital expenditure | $740,000 | $129,000 | $0 | $0 | $0 | $0 | $279,000 | $263,000 |
| Free cash flow | -$8.90M | -$12.81M | -$10.98M | $6.29M | -$11.22M | -$10.34M | -$14.56M | -$11.55M |
| Investing cash flow | -$740,000 | -$129,000 | $0 | $0 | $36,000 | $0 | -$279,000 | -$263,000 |
| Financing cash flow | $47.03M | $4,000 | $57,000 | $28.59M | $47.38M | $72,000 | -$151,000 | $73.06M |
| Depreciation & amortization | $500,000 | $500,000 | $520,000 | $372,000 | $400,000 | $400,000 | $421,000 | $418,000 |
| Stock-based compensation | $2.02M | $1.93M | $1.47M | $1.15M | $984,000 | $1.00M | $861,000 | $797,000 |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.